Down Syndrome Market

1. Down Syndrome Market Down Syndrome (DS) is a genetic disorder caused by presence of an extra copy of chromosome 21 making a total of 47 chromosome instead of 46. The condition is associated with intellectual disability, a characteristic facial appearance, and weak muscle tone (hypotonia) in infancy. DelveInsight's "Down Syndrome Market Insights, Epidemiology and Market Forecast- 2030" report delivers an in-depth understanding of the Down Syndrome, historical and forecasted epidemiology as well as the Down Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Geography Covered The United States EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan    Study Period: 2017-2030 Download syndrome-market Down Syndrome Disease Understanding and Treatment Algorithm People with DS may have a variety of birth defects and among these half of them are born with heart defect. Along with these, other conditions such as digestive abnormalities, leukemia and hypertension are also common. Patients with DS have increased risk of dementia with age having 70% chance of developing dementia after the age of 50. Physical features associated with DS include upward slanted eye, flattened facial profile and nose, short neck, small head, ear and mouth. full report @https://www.delveinsight.com/sample-request/down-

2. There are three types of DS: trisomy 21 (nondisjunction), translocation and mosaicism. 95% cases of DS are caused by Trisomy of chromosome 21. Trisomy 21 is caused by meiotic nondisjunction or abnormal segregation of chromosomes occurring mainly during maternal oogenesis (95%), particularly at meiosis I (MI) (80%). The DelveInsight Down Syndrome market report gives a thorough understanding of the Down Syndrome by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. Down Syndrome Epidemiology Down Syndrome (DS) is a chromosomal condition that is associated with intellectual disability, a characteristic facial appearance, and weak muscle tone (hypotonia) in infancy. All affected individuals experience cognitive delays, but the intellectual disability is usually mild to moderate. The Down Syndrome epidemiology division provide insights about historical and current Down Syndromepatient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. Key Findings  The total diagnosed prevalent population of DS in the 7MM was 545,992 in 2017 and estimated to rise at a significant rate during the study period (2017–2030).  According to the estimates, it was found that DS is most prominent in people of age 0–9 years. According to DelveInsight’s analysis, type specific diagnosed prevalent cases of DS were the maximum in Trisomy 21, followed by translocation and mosaicism among all the countries in the 7MM during the study period (2017–2030). Click here and download the epidemiology insights of the report. Down Syndrome Drug Chapters ACI-24 by AC immune, is a liposomal therapeutic anti-Abeta vaccine candidate, which generates antibodies specific to disease-causing conformations. The vaccine is designed to stimulate a patient's immune system to produce antibodies that specifically target the oligomeric and fibrillary Abeta proteins to prevent plaque accumulation and to enhance plaque clearance. Pentylenetetrazole (BTD-001), is under development by Balance Therapeutics. An orally administered drug candidate which is a small molecule GABA antagonist and is in Phase I stage of clinical development for the treatment of DS. Apart from the above mentioned molecules, there are few companies that are investigating their molecules in discovery or pre-clinical phase, those companies include, ManRos

3. Therapeutics (DYRK1A inhibitors), NeuroNascent (NNI-351), KinoPharma (KPO1143), Avanti Biosciences (ABI-02), Aelis Farma (AEF0217), Elixirgen Therapeutics (ZSCAN4), and NeuroCircuit Therapeutics. Since all the molecules are in discovery or preclinical phase, it is not possible to predict their market during our forecasted period (2020–2030). Drug chapter segment of the Down Syndrome report encloses the detailed analysis of Down Syndrome marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Down Syndromeclinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Click here and download pipeline https://www.delveinsight.com/report-store/down-syndrome-pipeline-insight Request for sample pages: https://www.delveinsight.com/sample-request/down- syndrome-market Down Syndrome Market Outlook DS is the most common genetic cause of severe learning disabilities in children associated with developmental delays, learning difficulties, health issues and some physical abnormalities. The current treatment targets symptoms but doesn’t target the underlying mechanisms causing the deficits. The treatment includes speech therapy, physical therapy, occupational therapy and special education. Drug therapy is not currently a component of standard care for DS. DS occurs due to chromosomal abnormalities. Being a genetic disorder, individuals affected with DS shows diverse symptoms. Therefore, a single approach or innovation cannot solve the purpose for different individuals with altered and varied needs. Thus, the market demands the emergence of products catering different needs. Life expectancy of individuals with DS has increased due to improvements in health care and decreased infant mortality and most importantly better non-invasive prenatal screening tests made available in the recent years. The life expectancy of an individual with DS tends to be in the 60’s. Persons with DS may be predisposed to certain illnesses and medical conditions, but that genetic arrangement does not guarantee their development. Thus, considering the current unmet needs, many companies are investing in the development of appropriate therapies for the treatment of DS. However, many of the recent clinical trials are poorly controlled and no controlled clinical studies for DS have demonstrated their good safety and efficacy. Also, with the rise in prenatal screening tests across US, the number of babies born with DS has significantly decreased. Many studies of drugs to treat symptoms of dementia in DS have included only a few participants. The results of these studies have not shown clear benefits of these drugs, either. insights of the report:

4. Similarly, studies of antioxidants for dementia in DS have shown that these supplements are safe, but not effective. The Down Syndrome market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Down Syndromemarkettrends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. Key Findings • Many companies are exploring various drugs to find an efficient therapy for the treatment of DS, including NeuroNascent (NNI-351), ManRos (DYRK1A inhibitors), AC Immune Therapeutics (ACI-24), and Balance Therapeutics (BTD-001), however some drugs lag behind either due to lack of efficacy and safety concerns, some are discontinued or some are in the very early stage of development process, thus market size estimation of these drugs at this stage is very early to predict. Download market insights of the report: https://www.delveinsight.com/report- store/down-syndrome-market Download sample pages of the report: request/down-syndrome-market https://www.delveinsight.com/sample-